Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO StudyMaria Alsina, Guillermo Villacampa, Carlos de Andrea, et al.
Journal of Cancer Research and Clinical Oncology|August 30, 2022
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registrySena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, et al.
Plos One|August 1, 2020
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registryAlmudena Cotes Sanchís, Javier Gallego, Raquel Hernandez, et al.
Therapeutic Advances in Medical Oncology|July 2, 2021
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registryPaula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 16, 2024
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registryAranzazu Arias-Martinez, Eva Martínez de Castro, Javier Gallego, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 2, 2021
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM RegistryFelipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al.
Therapeutic Advances in Medical Oncology|March 10, 2023
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapyPaula Jimenez-Fonseca, Victoria Foy, Sophie Raby, et al.
Plos One|May 9, 2023
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO studyManuel Sánchez-Cánovas, Paula Jimenez-Fonseca, David Fernández Garay, et al.
Pageof 4